Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
H Lundbeck A/S
HLUN-BH. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark. Address: Ottiliavej 9, Valby, Denmark, 2500
Analytics
WallStreetin tavoitehinta
360.27 DKKP/E-suhde
16.3908Osinkotuotto
1.61 %Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut HLUN-B
Osinkoanalytiikka HLUN-B
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
1 vuosiMaksusuhde 5 vuoden keskiarvo
25 %Osinkohistoria HLUN-B
Osakkeen arvostus HLUN-B
Talousasiat HLUN-B
Tuloksia | 2019 | Dynamiikka |